Abstract

Our study aimed to investigate the correlation of prostatic morphological parameters and benign prostatic hyperplasia (BPH) clinical progression in aging Chinese men. In this retrospective study, a total of 1038 patients were reviewed. Prostatic morphology was measured by transrectal ultrasound (TRUS). Detailed medical history of all candidates was recorded and analyzed after being classified by specific prostatic measurements. Univariate and multivariate logistic regression analyses were used to estimate the correlation between variables. The cumulative incidence of BPH clinical progression was 63.68% (661/1038) in the study population. Prostate volume (PV), transitional zone volume (TZV), transitional zone index (TZI), and intravesical prostatic protrusion (IPP) were all positively associated with BPH progression (all p < .001). Patients with a PV > 60 ml, TZV > 15 ml, TZI > 0.5, or IPP > 5 mm had a significantly higher possibility of overall BPH clinical progression (adjusted odds ratio (OR): 2.485, 1.678, 1.886, and 1.924, respectively; 95% confidence interval (CI): 1.559-3.960, 1.131-2.489, 1.379-2.579, and 1.357-2.728, correspondingly). Prostatic morphological parameters are significantly associated with BPH clinical progression. Patients with larger prostatic morphological parameters are more easily prone to clinical progress. As a result, reasonable managements should be timely considered for those patients before clinical progression occurs.

Highlights

  • Benign prostatic hyperplasia (BPH) is indisputable a common benign disease among aging males, which has a worldwide prevalence of over 50 % in men aged 60 years or older and as high as 88 % in men up to 80 years of age[1,2]

  • Prostate volume (PV), transitional zone volume (TZV), transitional zone index (TZI) and intravesical prostatic protrusion (IPP) were all positively associated with BPH progression

  • Prostatic morphological parameters are significantly associated with BPH clinical progression

Read more

Summary

Introduction

Benign prostatic hyperplasia (BPH) is indisputable a common benign disease among aging males, which has a worldwide prevalence of over 50 % in men aged 60 years or older and as high as 88 % in men up to 80 years of age[1,2]. BPH is not a life-threatening disease, it is associated with serious morbidities, including depression, an increased risk of falls and impaired quality of life (QoL)[3,4,5]. If it’s left untreated, lower urinary tract symptoms (LUTS) will get severer and serious complications such as hematuria, recurrent urinary tract infection (UTI), bladder stones, bladder diverticulum, acute urinary retention (AUR), and even renal insufficiency and failure can occur, which may be attributed to the disease progression[6] and requiring BPH-related surgical intervention[7]. Surgical interventions, including minimally invasive treatment are usually performed to improve symptoms and decrease disease progression in BPH patients who have developed BPH related complications[9]. Surgery associated morbidities, including blood loss, sexual dysfunction, instrument associated injury and even the resultant economic burden, etc. come out to be a real consideration

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call